Figure 1: Western Blot - Anti-Lamin A + C Antibody (A94336)
Western blot analysis of lysates from HeLa cells using Anti-Lamin A + C Antibody. The right hand lane represents a negative control, where the antibody is blocked by the immunising peptide.
Figure 2: Immunohistochemistry - Anti-Lamin A + C Antibody (A94336)
Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using Anti-Lamin A + C Antibody. The right hand panel represents a negative control, where the antibody was pre-incubated with the immunising peptide.
Figure 3: Immunofluorescence - Anti-Lamin A + C Antibody (A94336)
Immunofluorescence analysis of HeLa cells using Anti-Lamin A + C Antibody. The right hand panel represents a negative control, where the antibody was pre-incubated with the immunising peptide.
Figure 6: Immunohistochemistry - Anti-Lamin A + C Antibody (A94336)
Immunohistochemical analysis of paraffin-embedded human uterus tissue using Anti-Lamin A + C Antibody at 1:200 (4°C overnight). Negative control was secondary antibody only.
Figure 7: Immunohistochemistry - Anti-Lamin A + C Antibody (A94336)
Immunohistochemical analysis of paraffin-embedded human uterus cancer tissue using Anti-Lamin A + C Antibody at 1:200 (4°C overnight). Negative control was secondary antibody only.
Figure 8: Immunofluorescence - Anti-Lamin A + C Antibody (A94336)
Immunofluorescence analysis of mouse kidney tissue using Anti-Lamin A + C Antibody (red) at 1:200 (4°C overnight). Cy3 labelled secondary antibody was used at 1:300 (RT 50min). Panel A: Target. Panel B: DAPI. Panel C: Merge.
Figure 9: Immunofluorescence - Anti-Lamin A + C Antibody (A94336)
Immunofluorescence analysis of human liver tissue using Anti-Lamin A + C Antibody (red) at 1:200 (4°C overnight). Cy3 labelled secondary antibody was used at 1:300 (RT 50min). Panel A: Target. Panel B: DAPI. Panel C: Merge.
